Gastrointestinal Stromal Tumors Clinical Trial
Official title:
Accuracy and Feasibility of a Morpho-anatomical Classification Oriented Laparoscopic Resection of Gastric Stromal Tumors in Advanced Laparoscopic Surgery Center: a Prospective Cohort Study
Despite laparoscopic surgical treatment has not been recommended in patients with gastric gastrointestinal stromal tumors (GIST) larger than 5 centimeter, but it continues to evolve rapidly to overcome the boundaries. Therefore the authors generated a morpho-anatomical classification system (MACS) adapted for primary gastric GISTs, by which they could plan to tailor the laparoscopic gastric resection appropriately. The aims of the study was to demonstrate the feasibility of laparoscopic surgery for primary gastric GISTs larger than 5 cm, to find out the accuracy and practicality of the MACS for the development a preoperative strategy and the extent to which this strategy overlaps with the reality.
Incidence rate of gastrointestinal stromal tumors (GIST) is 10-15 per million per year.
Although very rare, it is the most common mesenchymal tumor of the gastrointestinal tract,
and the stomach is the most common affected organ with up to 55.6%. Despite recent drug
discoveries have greatly impacted the treatment, complete surgical resection with adequate
safety margin is still the only potentially curative treatment for primary gastric GIST with
no evidence of metastasis. As sarcomas in general, most GISTs also metastasize
hematogenously to the liver, disseminate peritoneally, and rarely show lymph node
metastasis, therefore systematic or prophylactic lymph node dissection is usually
unnecessary; a pick-up sampling is considered sufficient when a perilesional lymph node
enlargement is found. In addition to that, these tumors tend to be soft and friable.
Therefore pseudocapsule may be tearing spontaneously or inadvertently during surgery and
tumor cells can be disseminating intraperitoneally which results in increased risk for
recurrence and decreased survival.
Considering these properties of the tumor, the goals of surgery for primary gastric GIST are
handling the tumor with great care to avoid tumor rupture as well as performing a complete
resection with a negative surgical margin and preserving the organ function as much as
possible. This can be accomplished by the traditional open, or more recently by the various
total or hybrid laparoscopic techniques. Despite laparoscopic surgical treatment of the
GISTs had not been recommended owing to the higher risk of tumor rupture and subsequent
peritoneal seeding in consensus meetings in the United States and Europe in 2004 and 2005
respectively, it has experienced a rapid and major evolutionary process and currently it is
being advised to be a standard approach for gastric GISTs irrespective of its size or
location.
In addition to achieve an R0 resection without a tear in the tumor, the most important issue
for the laparoscopic gastric GIST surgery is the preserving the function and not to cause a
stenosis in the stomach as much as possible. According to the morphologic characteristics of
the tumor and the area in the three-dimensional anatomical configuration of the stomach that
involved by the tumor, a lot of laparoscopic surgical scenarios can be produced. Among them,
to achieve the best alternative which meets all above criteria the authors generated a
morpho-anatomical classification system by which they could plan preoperatively to tailor
the gastric resection and all operational requirements. This system was partly inspired by
the TNM classification for GISTs and Japanese classification of gastric carcinoma, has long
been used in authors' institution when planning a laparoscopic intervention for various
gastric lesions in patients in whom an appropriate preoperative patient evaluation is
needed. It is then specifically composed and standardized to adapt for primary gastric GISTs
and it was being used for large tumors up to 10 cm.
The aims of the study was to demonstrate the feasibility of laparoscopic surgery for primary
gastric GISTs larger than 5 cm, to find out the accuracy and practicality of the
classification system in the development a preoperative strategy and the extent to which
this strategy overlaps with the reality.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05385549 -
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
|
Phase 2 | |
Recruiting |
NCT05905887 -
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT01933958 -
Regorafenib Post-marketing Surveillance in Japan
|
||
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT01440959 -
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
|
Phase 2 | |
Completed |
NCT00718562 -
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
|
Phase 2 | |
Completed |
NCT00385203 -
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
|
Phase 2 | |
Completed |
NCT00137449 -
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00237172 -
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
|
Phase 2 | |
Terminated |
NCT04409223 -
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
|
Phase 3 | |
Active, not recruiting |
NCT03556384 -
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Recruiting |
NCT04106024 -
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
|
Phase 2 | |
Completed |
NCT02171286 -
The Oncopanel Pilot (TOP) Study
|
N/A | |
Completed |
NCT01114087 -
Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility
|
N/A | |
Recruiting |
NCT05366816 -
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
|
Phase 2 | |
Recruiting |
NCT03602092 -
Observational Registry Data on GIST Patients
|
||
Recruiting |
NCT05197933 -
Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
|
N/A | |
Completed |
NCT02931929 -
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05080621 -
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
|
Phase 1/Phase 2 | |
Completed |
NCT02607332 -
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
|
Phase 2 |